Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

References

• Al-HerzWBousfihaACasanovaJLPrimary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary ImmunodeficiencyFront Immunol201125412622566792
   PubMed Web of Science ®Google Scholar
• BrutonOCAgammaglobulinemiaPediatrics1952972272814929630
   PubMed Web of Science ®Google Scholar
• BergerMCuppsTRFauciASImmunoglobulin replacement therapy by slow subcutaneous infusionAnn Intern Med198093155567396316
   PubMed Web of Science ®Google Scholar
• RoordJJvan der MeerJWKuisMHome treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulinLancet1982182736896906175862
   PubMed Web of Science ®Google Scholar
• UgazioAGDuseMReRMangiliGBurgioGRSubcutaneous infusions of gammaglobulins in management of agammaglobulinaemiaLancet198231982652266172685
   PubMed Web of Science ®Google Scholar
• WelchMJStiehmERSlow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulinJ Clin Immunol1983332852866885970
   PubMed Web of Science ®Google Scholar
• GardulfAHammarstromLSmithCLHome treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusionLancet199133887601621661712881
   PubMed Web of Science ®Google Scholar
• fda.gov [homepage on the Internet]. January 9, 2006 approval letter for VivaglobinSilver Spring, MDUS Food and Drug Administration [updated 2011 April 8]. Available from: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/Approvedproducts/licensedproductsBLAs/fractionatedplasmaproducts/UCM070367.htm. Accessed April 24, 2012.
   Google Scholar
• Gammagard liquid® (immune globulin infusion, human, 10%) [prescribing information]West Lake Village, CABaxter Healthcare Corporation2012
   Google Scholar
• Gammaked™ (immune globulin injection, human, 10%) [prescribing information]Research Triangle Park, NCTalecris Biotherapeutics, Inc.2011
   Google Scholar
• Gamunex-C (immune globulin injection, human, 10%) [prescribing information]Research Triangle Park, NCTalecris Biotherapeutics, Inc.2010
   Google Scholar
• Hizentra (immune globulin subcutaneous, human, 20% liquid) [prescribing information]Kankakee, ILCSL Behring LLC2011
   Google Scholar
• LeeDCStenlandCJHartwellRCMonitoring plasma processing steps with a sensitive Western Blot assay for the detection of the prion proteinJ Virol Methods2000841778910644089
   PubMed Web of Science ®Google Scholar
• StenlandCJLeeDCBrownPPartitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasmaTransfusion200242149750012421224
   PubMed Web of Science ®Google Scholar
• StruckiMBoschettiNSchaferWInvestigations of prion and virus safety of a new liquid IVIG productBiologicals200836423924718337119
   PubMed Web of Science ®Google Scholar
• MankariousSLeeMFischerSThe half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulinJ Lab Clin Med198811256346403183495
   PubMed Web of Science ®Google Scholar
• WaldmanTAStroberWBlaeseRMMetabolism of immunoglobulinsProg Allergy19691311104186070
   PubMedGoogle Scholar
• WaniewskiIGardulfAHammarströmLBioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiencyJ Clin Immunol199414290977515071
   PubMed Web of Science ®Google Scholar
• BorteMPacMSerbanMEfficacy and safety of Hizentra, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with Primary ImmunodeficiencyJ Clin Immunol20113175276121674136
   PubMed Web of Science ®Google Scholar
• WassermanRLIraniAMTracyJPharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency diseaseClin Exp Immunol201016151852620550549
   PubMed Web of Science ®Google Scholar
• OchsHDGuptaSKiesslingPNicolayUBergerMSafety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseasesJ Clin Immunol200626326527316783465
   PubMed Web of Science ®Google Scholar
• GardulfANicolayUAsensioORapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national studyJ Clin Immunol200626217718516758340
   PubMed Web of Science ®Google Scholar
• DesaiSHChoukseyAPollJBergerMA pilot study of equal doses of 10% IGIV given intravenously or subcutaneouslyJ Allergy Clin Immunol200912485485619767071
   PubMed Web of Science ®Google Scholar
• Vivaglobin® (immune globulin subcutaneous, human, 16%) [prescribing information]Kankakee, ILCSL Behring, LLC2010
   Google Scholar
• OchsHDPinciaroPJThe Octogam study group, Octogam 5% an intravenous IgG product is efficacious and well tolerated in subjects with primary immunodeficneicy diseasesJ Clin Immunol20042430931415114062
   PubMed Web of Science ®Google Scholar
• BallowMSafety of IGIV therapy and infusion related adverse eventsImmunol Res20073812213217917017
   PubMed Web of Science ®Google Scholar
• GardulfANicolayUMathDChildren and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJ Allergy Clin Immunol200411493694215480339
   PubMed Web of Science ®Google Scholar
• Immune Deficiency FoundationTreatment Experiences and Preferences of Patients with Primary Immune Deficiency Diseases: First National Survey 20026202003 Available from: http://primaryimmune.org/about-primary-immunodeficiency-diseases/idf-publications?aid=1266&pid=275&sa=1. Accessed April 2, 2012
   Google Scholar
• NicolayUKiesslingPBergerMHealth-related quality of life and treatment satisfaction in North American patients with Primary Immunedefiency Diseases receiving subcutaneous IgG self-infusions at homeJ Clin Immunol200626657216418804
   PubMed Web of Science ®Google Scholar
• BayrakciBErsoyFSanalOThe efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficienciesTurk J Pediatr20054723924616250308
   PubMed Web of Science ®Google Scholar
• BussePJRazviSCunningham-RundlesCEfficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiencyJ Allergy Clin Immunol20021091001100412063531
   PubMed Web of Science ®Google Scholar
• LieseJGWintergerstUTympnerKDBelohradskyBHHigh- vs lowdose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemiaAm J Dis Child19921463353391543181
   PubMedGoogle Scholar
• NolteMTPirofskyBGerritzGAGoldingBIntravenous immunoglobulin therapy for antibody deficiencyClin Exp Immunol197936237243477026
   PubMed Web of Science ®Google Scholar
• PourpakZAghamohammadiASedighipourLEffect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiencyJ Microbiol Immunol Infect20063911412016604243
   PubMedGoogle Scholar
• RoifmanCMLedermanHMLaviSSteinLDLevisonHGelfandEWBenefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary diseaseAm J Med1985791711744025374
   PubMed Web of Science ®Google Scholar
• ChapelHMSpickettGPEricsonDEnglWEiblMMBjorkanderJThe comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapyJ Clin Immunol2000209410010821460
   PubMed Web of Science ®Google Scholar
• BergerMMurphyERileyPBergmanGEVIRTUE Trial InvestigatorsImproved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency disease during self-treatment with subcutaneous immunoglobulin GSouth Med J2010103985686320689467
   PubMed Web of Science ®Google Scholar
• HaganJBFasanoMBSpectorSEfficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyJ Clin Immunol20103073474520454851
   PubMed Web of Science ®Google Scholar
• JollesSBernatowskaEde GraciaJEfficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapyClin Immunol20111419010221705277
   PubMed Web of Science ®Google Scholar
• WassermanRLMelamedIKobrynskiLEfficacy, safety and pharmacokinetics of a 10% liquid immune globulin preparation (GAM-MAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseJ Clin Immunol20113132333121424824
   PubMed Web of Science ®Google Scholar
• OrangeJSGrossmanWJNavickisRJWilkesMMImpact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studiesClin Immunol2010137213020675197
   PubMed Web of Science ®Google Scholar
• LucasMLeeMLortanJInfection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 yearsJ Allergy Clin Immunol20101251354136020471071
   PubMed Web of Science ®Google Scholar
• EijkhoutHWvan Der MeerJWKallenbergCGThe effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trialAnn Intern Med2001135316517411487483
   PubMed Web of Science ®Google Scholar
• RoifmanCMLevisonHGelfandEWHigh-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung diseaseLancet198718541107510772883406
   PubMed Web of Science ®Google Scholar
• ShehataNPaldaVBowenTThe use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guidelineTransfus Med Rev201024S28S5019962579
   PubMed Web of Science ®Google Scholar
• QuartierPDebréMDe BlicJEarly and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patientsJ Pediatr199913458959610228295
   PubMed Web of Science ®Google Scholar
• RoifmanCMSchroederHBergerMComparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized doubleblind trialInt Immunopharmacol200331325133312890430
   PubMed Web of Science ®Google Scholar
• BergerMPrinciples of and advances in immunoglobulin replacement therapy for primary immunodeficiencyImmunol Allergy Clin North Am200828241343718424340
   PubMed Web of Science ®Google Scholar
• BonaguraVRMarchlewskiRCoxARosenthalDWBiologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infectionJ Allergy Clin Immunol2008122121021218602574
   PubMed Web of Science ®Google Scholar
• Cunningham-RundlesCHow I treat common variable immune deficiencyBlood201011671520332369
   PubMed Web of Science ®Google Scholar
• BergerMIncidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDDJ Clin immunol20113192492621643892
   PubMed Web of Science ®Google Scholar
• KhanSGrimbacherBBoeckingCSerum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapyDrug Metab Lett2011513213621457142
   PubMedGoogle Scholar
• BergerMRojavinMKiesslingPZenkerOPharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficienciesClin Immunol201113913314121353644
   PubMed Web of Science ®Google Scholar
• QuintiISoresinaAGuerraAEffectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort studyJ Clin Immunol20113131532221365217
   PubMed Web of Science ®Google Scholar
• ChapelHCunningham-RundlesCUpdate in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditionsBr J Haematol200914570972719344423
   PubMed Web of Science ®Google Scholar
• RoifmanCMBergerMNotarangeloLDManagement of primary antibody deficiency with replacement therapy: summary of guidelinesImmunol Allergy Clin North Am200828487587618940580
   PubMed Web of Science ®Google Scholar
• YongPIBoyleJBallowMUse of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and ImmunologyClin Immunol2010135225526319914873
   PubMed Web of Science ®Google Scholar
• GardulfABjorvellHGustafsonRSafety of rapid subcutaneous gamma-globulin infusions in patients with primary antibody deficiencyImmunodeficiency1993481847513227
   PubMedGoogle Scholar
• GasparJGerritsenBJonesAImmunoglobulin replacement treatment by rapid subcutaneous infusionArch Dis Child19987948519771252
   PubMed Web of Science ®Google Scholar
• HansenSGustafsonRSmithCIGardulfAExpress subcutaneous IgG infusions: decreased time of delivery with maintained safetyClin Immunol200210423724112217333
   PubMed Web of Science ®Google Scholar
• ShapiroRSubcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysisJ Clin Immunol20103030130720082124
   PubMed Web of Science ®Google Scholar
• BergerMSubcutaneous administration of IgGImmunol Allergy Clin North Amer200828477980218940574
   PubMed Web of Science ®Google Scholar
• Gamunex-c.com [homepage on the Internet]. Gamunex-C PI SubQ Infusion VideoUSATalecris Biotherapeutics2010 Available from: http://www.gamunex-c.com/patient-connexions-support-patient-education-PI.htm. Accessed April 30, 2012
   Google Scholar
• Gammagard.com [homepage on the Internet]. How to infuse: subcutaneous administration of Gammagard liquidWestlake Village, CABaxter Healthcare Corporation2011 Available from: http://www.gammagard.com/patients-and-families/help-for-patients/patient-education.html. Accessed April 30, 2012
   Google Scholar
• hizentra.com [homepage on the Internet]. Self-Administration VideoKankakee, ILCSL Behring, LLC2010 Available from: www.hizentra.com/consumer/about-hizentra/sub-q-self-administration-video.aspx. Accessed April 30, 2012
   Google Scholar
• primaryimmune.org [homepage on the Internet]. Online accredited course for nurses about primary immunodeficiency and immunoglobulin therapyTowson, MDImmune Deficiency Foundation2011 Available from: http://primaryimmune.org/2011/09/idf-launches-free-accredited-course-for-nurses-about-primary-immunodeficiency-and-immunoglobulin-therapy. Accessed April 30, 2012.
   Google Scholar
• hizentra.com [homepage on the Internet]. SHARE nurse trainingKankakee, ILCSL Behring, LLC2012 Available from: http://www.hizentra.com/share/default.aspx. Accessed April 30, 2012
   Google Scholar
• BergerMPinciaroPJSafety, efficacy, and pharmacokinetics of Flebogamma 5% immune globulin intravenous (human) for replacement therapy in primary immunodeficiency diseasesJ Clin Immunol200424438939615163895
   PubMed Web of Science ®Google Scholar
• ChurchJALeiblHSteinMREfficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiencyJ Clin Immunol20062638839516705486
   PubMed Web of Science ®Google Scholar
• SteinMNelsonRChurchJSafety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficienciesJ Clin Immunol20092913714418814020
   PubMed Web of Science ®Google Scholar
• WassermanRChurchJSteinMSafety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyJ Clin Immunol362012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• BrennanVMSalome-BentleyNJChapelHMProspective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulinClin Exp Immunol200313324725112869031
   PubMed Web of Science ®Google Scholar
• GardulfAAndersonVBjorkanderJSubcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsLancet199534589463653697845120
   PubMed Web of Science ®Google Scholar
• RadinskySBonaguraVRSubcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulinJ Allergy Clin Immunol2003112363063313679829
   PubMed Web of Science ®Google Scholar
• EpsteinJSZoonKCDear doctor letter - important drug warning: immune globulin intravenous (human). FDA Med WatchUS Food and Drug Administration1998 Available from: http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm105914.htm. Accessed July 14, 2012
   Google Scholar
• PierceLRJainNRisks associated with the use of intravenous immunoglobulinTransfusion Med Rev2003174241251
   Web of Science ®Google Scholar
• DalakasMCHigh-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic eventsNeurology1994442232268309562
   PubMed Web of Science ®Google Scholar
• DanielGWMenisMSridharGImmune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010Transfusion3122012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• OvanesovMVLaboratory investigations of products associated with thrombotic eventsFDA Workshop: Risk Mitigation Strategies to Address Procoagulant Activity in Immune Globulin ProductsBethesda, MDUS Food and Drug Administration2011 Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM260788.pdf. Accessed
   Google Scholar
• NicolayUHaagSEichmannFHergetSSpruckDGardulfAMeasuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapyQual Life Res2005141683169116119180
   PubMed Web of Science ®Google Scholar
• FasthANystromJQuality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulinJ Clin Immunol20082837037818256911
   PubMed Web of Science ®Google Scholar
• KittnerJMGrimbacherBWulffWJägerBSchmidtREPatients’ attitude to subcutaneous immunoglobulin substitution as home therapyJ Clin Immunol20062640040516783533
   PubMed Web of Science ®Google Scholar
• HoffmannFGrimbacherBThielJPeterHHBelohradskyBHVivaglobin Study GroupHome-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiencyEur J Med Res201015623824520696632
   PubMed Web of Science ®Google Scholar
• FasthANystromJSafety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiencyActa Paediatrica2007961474147817850391
   PubMed Web of Science ®Google Scholar
• GardulfAAnderssonELindqvistMRapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient womenJ Clin Immunol20012115015411332654
   PubMed Web of Science ®Google Scholar
• SundinUNavaSHammarstromLInduction of unresponsiveness against IgA in IgA- deficient patients on subcutaneous immunoglobulin infusion therapyClin Exp Immunol19981123413469649200
   PubMed Web of Science ®Google Scholar
• KollerHSchroeterMFeischenHHartungHPKieseierBCSubcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathiesJ Neurol2006253111505150616972122
   PubMed Web of Science ®Google Scholar
• MisbahSKuijpersTvan der HeijdenJGrimbacherBGuzmanDOrangeJBringing immunoglobulin knowledge up to date: how should we treat today?Clin Exp Immunol2011166162521762127
   PubMed Web of Science ®Google Scholar
• KnightECarneENovakBSelf-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiencyJ Clin Pathol20106384684720671049
   PubMed Web of Science ®Google Scholar
• SchiffRIWassermanRSteinMRecombinant human hyaluroni-dase facilitates dispersion of subcutaneously administered gammagard liquid, enabling administration of full monthly dose in single site with improved bioavailability in immunodeficient patients [abstract]Clin Exp Immunol2008154Suppl 1121
   Google Scholar
• MelamedIRSteinMRWassermanRLRecombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard liquid and enables administration of a full monthly dose in a single site to patients with immunodeficiency diseases [abstract]J Allergy Clin Immunol20081212 Suppl 1S83
   Web of Science ®Google Scholar
• SteinMWassermanRLMelamedIPharmacokinetics (PK) of human immunoglobulin 10% (IgG) administered intravenously (IGIV), subcutaneously (IGSC) or facilitated subcutaneously with recombinant human hyaluronidase (IGHy) in a subset of patients with Primary Immunodeficiency Disease (PIDD)J Allergy Clin Immunol201229AB14
   Google Scholar
• WassermanRLMelamedISteinMTolerability and efficacy of facilitated-subcutaneous infusion of immune globulin (Human), 10% and recombinant human hyaluronidase (IGHy) in a subset of study patients with Primary Immunodeficiency Disease (PIDD)J Allergy Clin Immunol201229AB15
   Google Scholar